Sorry, you need to enable JavaScript to visit this website.
Home Science Clinical Trials Integrity and Transparency

As we work to develop new medicines, our strict standards of moral and ethical conduct are guided by the help and oversight of institutional review boards, regulatory authorities, and industry association guidelines governing ethical clinical trial conduct and research integrity. Additionally, we have created our own agency to oversee our research ethics and integrity. 

All Pfizer-sponsored interventional studies are conducted in accordance with applicable laws and regulations, as well as principles derived from relevant international standards including: 

  • The Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines 

  • The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 guideline for Good Clinical Practice 

  • PhRMA’s Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results 

  • The Declaration of Helsinki 

  • The United States Belmont report 

We strive to maintain the highest ethical, scientific, and clinical standards in all our clinical research around the world. We regularly review our policies to align them with Pfizer's vision, values, and goals, and with our stakeholders' evolving priorities.

Our Bioethics Advisory Council (BAC) is an external group of ethicists, clinical researchers, patient advocates, and academics. All of whom provide Pfizer with independent, expert perspectives on globally complex issues at the crossroads of research, medicine, and ethics. The panel’s guidance on emerging issues and scientific trends helps to inform our R&D planning, as well as other policies across our portfolio, and the lifecycle of our medicines. In so doing, the panel aims to ensure that the interests of the patient and the public remain at the core of our activities. The panel addresses a broad range of topics including: 

  • Conducting clinical research in vulnerable patient populations 
  • The use, privacy, and security of patient data 
  • Emerging access, emerging therapies, and our relationships with academic, research, and patient communities  

The BAC is sponsored by Pfizer’s Chief Medical Officer

Bartha Knoppers, PhD, MA, LLB/BCL, Professor and Director of the Centre of Genomics and Policy, Faculty of Medicine, Human Genetics, McGill University, Montreal (Quebec), Canada 

James Lavery, PhD, Professor and Hilton Chair in Global Health Ethics Rollins School of Public Health, Emory University, US 

Science

Making the COVID-19 Oral Treatment: How 2,000+ Pfizer Team Members Made It Happen

As the potential threat of COVID-19 became clear by early 2020, teams across Pfizer sprang into action. Together, they worked to better understand the novel virus.

paxlovid_stability_testing_785x440.jpg
Our Purpose

Net Zero by 2040: How Pfizer is Fighting Climate Change with Ambitious Science Based Goals

In 2015, on the eve of the Paris Agreement, Pfizer was one of the first companies in the world to seek and gain approval of its greenhouse gas emission reduction goal.
Carbon Neutral by 2030: How Pfizer is Fighting Climate Change with Ambitious Science Based Goals
Our People

Thrive with Pride

Pfizer is honored to share the 16th anniversary edition of our Pride Journal - a platform where our LGBTQ+ Pfizer Colleagues and allies can share personal experiences of struggles, triumph, and their hope for the future in honor of Pride Month.
Thrive with Pride - 2022 Pride Journal

We proudly partner with thousands of study sites and tens of thousands of trial participants around the world. It’s these clinical trials that lead to life-changing medicines.

Go to Pfizer Clinical Trials Site
  • 00Phase 1
  • 00Phase 2
  • 00Phase 3
  • 00Registration
  • 00Total